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Systemic lupus erythematosus (SLE) is an autoim-
mune disease of unknown cause in which multiple 
organs are damaged by various autoantibodies and 
immune complexes [1].  Although SLE is usually 
improved by treatment with glucocorticoids (GCs) and/
or immunosuppressants (ISs),  patients may exhibit a 
cycle of remission and exacerbation that follows a 
refractory course.
Hench first reported the effectiveness of GCs for 
individuals with rheumatoid arthritis in 1948 [2],  and 
Kendall,  Hench,  and Reichstein were awarded the 
Nobel prize for this discovery in 1950.  Dubois reported 
the effectiveness of the GCs prednisone and predniso-
lone in SLE patients in 1956 [3].  Since then,  GCs have 
played a central role in the treatment of SLE.  The prog-
nosis of SLE has improved from a 5-year survival rate 
< 50% in 1955 [4] to a recent 10-year survival rate > 90% 
[5 , 6].  With the advent of antimalarials and various ISs,  
the treatment of SLE has changed,  but the role of GCs 
has not diminished.
Because GCs also have many detrimental effects,  
their initial and maintenance doses should be as low as 
possible while still providing a sufficient therapeutic 
effect [7].  In 1994,  the Textbook of Clinical Rheuma-
tology recommended the following guideline for treat-
ing SLE with GCs: “Continue treatment for 4 to 8 
weeks until activity is reduced,  and then taper.  In prin-
ciple,  the taper rate is 10% over 2 weeks,  with monitor-
ing of disease activity” [8-10].  In contrast,  a consensus 
report in 2004 by the Ad Hoc Working Group on 
Steroid-Sparing Criteria in Lupus [11] recommended 
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that the administration of a GC to patients with severe 
SLE should be tapered by 5 mg/week as prednisolone 
equivalents during the first several weeks.  However,  no 
clinical trials have directly compared these 2 tapering 
methods.
Several clinical guidelines have been published in 
recent years regarding the definition of severe SLE.  
Most of these include the following: rash involving 
> 2/9 body surface area,  myositis,  severe pleurisy and/
or pericarditis with effusion,  ascites,  enteritis,  myelop-
athy,  psychosis,  acute confusion,  optic neuritis,  plate-
lets < 25 × 109/L,  or class III or IV ± V lupus nephritis 
[7 , 12 , 13].  The most commonly used SLE classification 
criteria are those of the 1997 American College of Rheu-
matology (ACR) and the Systemic Lupus International 
Collaborating Clinics (SLICC) system [14 , 15].  The SLE 
Disease Activity Index-2K (SLEDAI-2K) and the British 
Isles Lupus Assessment Group Index (BILAG) are often 
used for the measurement of SLE disease activity 
[16 , 17].  The Lupus Low Disease Activity State (LLDAS) 
was defined recently as a possible target when treating 
SLE [18].
We designed a trial to evaluate the usefulness of 
rapid GC tapering (5 mg/week) in a comparison with 
conventional tapering (5 mg/2 weeks).  The primary 
endpoint will be the relapse-free survival rate at week 
52,  and the major secondary endpoint will be the prev-
alence of the LLDAS at week 52.
Endpoints
Primary outcome measure. The primary out-
come measure will be the number of patients in each 
treatment arm who die or who are diagnosed with a 
major SLE flare,  based on one or more of the following 
criteria after the remission or low disease activity state 
accompanied by an SLEDAI value ≤ 4: (1) a > 12-point 
change in the SLEDAI value; or (2) a new onset or 
worsening of central nervous system (CNS)-SLE,  vas-
culitis,  nephritis,  myositis,  thrombocytopenia (platelet 
count < 60,000),  or hemolytic anemia (hemoglobin 
< 7 mg/dl) requiring the doubling of the patient’s pred-
nisone dose or a dose > 0.5 mg/kg/day; or (3) the use of 
new ISs; or (4) an increase in the patient’s Physician 
Global Assessment score to > 2.5 [19].
Secondary outcome measures. The secondary 
outcome measures are the following parameters at 52,  
104,  and 156 weeks,  respectively: (1) the relapse-free 
survival rate,  (2) the prevalence of LLDAS,  (3) the 
cumulative dose of GCs,  (4) the maintenance dose of 
GCs,  and (5) the rate of comorbid infection requiring 
hospitalization.  The definition of the LLDAS was as 
follows: (1) SLEDAI ≤ 4,  with no activity in major 
organ systems (i.e.,  renal,  CNS,  cardiopulmonary,  vas-
culitis,  fever) and no hemolytic anemia or gastrointes-
tinal activity; (2) no new lupus disease activity com-
pared with the previous assessment; (3) a Physician 
Global Assessment ≤1 (scale 0-3); (4) a current pred-
nisolone (or equivalent) dose ≤ 7.5 mg/day; and (5) 
well-tolerated standard maintenance doses of immuno-
suppressive drugs and approved biological agents.  The 
maintenance dose of GCs was defined as the dose of 
GCs at the last observation in patients with remission or 
a low disease activity state.
Eligibility Criteria
The target population will be patients who fulfill the 
classification criteria described below for SLE and who 
are admitted to our 2 hospitals (see below).
Inclusion criteria. The inclusion criteria are as 
follows: (1) men and women aged > 20 years,  (2) with 
the ability and willingness to provide written informed 
consent,  (3) fulfilling the 1997 ACR SLE classification 
criteria or the SLICC SLE classification criteria and a 
prior diagnosis of SLE [14 , 15],  (4) current treatment 
with ≥ 0.5 mg/kg/day and > 40 mg/day of oral predniso-
lone or an equivalent doses of a GC with or without any 
IS,  and not yet tapered in this term.
Exclusion criteria. The exclusion criteria are as 
follows: (1) unable to provide informed consent,  (2) 
experiencing currently uncontrollable complications,  
(3) currently pregnant or nursing,  and (4) men or 
women who have a pregnancy planned within 52 weeks,  
(5) patients who have never achieved remission or a low 
disease activity state within the observation period.  The 
remission or low disease activity state was defined as an 
SLEDAI value ≤ 4.
Methods
Aim and design. This is a 52-week,  randomized,  
open-label,  two-arm,  parallel-group,  multicenter con-
trolled trial.  It is a pragmatic clinical trial designed to 
identify the optimal method of GC tapering in patients 
with severe SLE.  Figure 1 is the study flow chart.
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The conventional GC tapering group will receive 
initial GC treatment for 2 or 4 weeks,  and then the GC 
will be tapered by 10 mg once every 2 weeks to 50 mg/
day,  then tapered by 5 mg every 2 weeks to 40 mg/day,  
and finally tapered by 2.5 mg every 2 weeks to 30 mg/
day.
The rapid GC tapering group will receive initial GC 
treatment for 2 or 4 weeks and then the GC dose will be 
tapered by 10 mg/week to 50 mg/day and then tapered 
by 5 mg/week to 30 mg/day.  The taper rate for doses 
< 30 mg/day will be left to each physician’s discretion.
The trial hypothesis is that at week 52,  the rapid-ta-
pering group will have a lower cumulative GC dose than 
the conventional-therapy group but a similar relapse-
free survival rate.
Setting. This trial will be conducted at two hospi-
tals: the Juntendo University Hospital and the Juntendo 
University Nerima Hospital,  both in Tokyo,  Japan.
Ethical considerations and registration. This 
study will be conducted in accord with the Declaration 
of Helsinki and the Ethics Guidelines for Clinical 
Research issued by Japan’s Ministry of Health,  Labour,  
and Welfare.  Informed consent will be obtained from 
all patients before the registration.  The trial has been 
approved by the Ethics Committees of both hospitals 
involved in the study and has been reviewed and 
approved by the Ethics Committee of Juntendo 
University Hospital (J18-004).  The study was registered 
at the Japan Registry of Clinical Trials as no. 
jRCT1031180196.
Withdrawal of participants. Participants will 
have the right to withdraw from this study at any time 
for any reason.
Randomization. One hundred patients will be 
recruited from the 2 hospitals and then randomly allo-
cated in a 1 : 1 ratio using an online database to either 
the conventional GC tapering group or the rapid GC 
tapering group,  with block randomization.  The 
patients will be randomized automatically on the day of 
website registration.  Blocked randomization will be 
performed in the following 2 blocks: (A) lupus nephri-
tis,  neuropsychiatric SLE,  other; and (B) with or with-
out steroid pulse.
Adverse effects and safety. Adverse effects will be 
recorded as part of the data collection at each time point 
and will be reported to clinical authorities and the 
Ethics Committee.  Participants experiencing adverse 
effects will be referred for appropriate treatment.
Routine clinical practice. All other clinical pro-
cedures (including any IS administration and blood 
examinations) will be performed according to the rou-
tine practice of each hospital,  and independently of the 
trial allocation.  In particular,  the frequency with which 
blood and urine examinations are performed will be 
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Fig. 1　 General schema of allocation.
based on existing protocols and clinician preferences.
Statistical Considerations
Sample size. One hundred patients are to be 
recruited from the 2 hospitals and randomly allocated in 
a 1 : 1 ratio.  As this is a non-inferiority trial,  the sam-
ple size calculation is based on the baseline relapse-free 
survival rate of 96.2% identified in our previous study 
[20],  as well as a clinically relevant non-inferiority mar-
gin of 10%,  a one-sided alpha of 2.5% (equivalent to a 
two-sided alpha of 5%),  and < 10% protocol violations.  
Due to this anticipated protocol violation rate,  a larger 
number of patients than statistically necessary will be 
recruited to the full study,  as not all patients will be 
included in the final analysis.
Outcome analysis. The outcome measures of this 
trial will be defined in terms of the numbers of recruited 
and randomized patients,  the protocol fidelity,  and the 
follow-up rates by trial arm.  These statistics will inform 
a Consolidated Standards of Reporting Trials 
(CONSORT) diagram reporting the patient recruit-
ment,  treatment,  and retention.  All data will be coded,  
locked,  and stored in the study office.  The trial will be 
self-monitored at its initiation and at the end of the trial,  
and at least 1 × /year.
The patients’ baseline characteristics,  the treat-
ment(s) of their underlying diseases or comorbidities,  
and their demographic factors will be summarized for 
each randomized group.  The multiple imputation 
method will be used to impute missing primary or sec-
ondary outcomes.  For the comparison of the outcomes 
between groups,  the Mann-Whitney U-test will be used 
for non-normally distributed variables.  Categorical 
variables will be compared using Fisher’s exact test.  The 
relapse-free survival rate of each group will be com-
pared with Kaplan-Meier curves that are plotted and 
evaluated using the log-rank test.
Discussion
This study is intended to investigate whether rapid 
GC tapering is non-inferior to conventional GC taper-
ing with regard to the relapse-free survival rate.  We will 
determine the prevalence of LLDAS,  the cumulative 
doses of GCs,  and comorbidities.  If our hypothesis 
(i.e.,  that rapid GC tapering is non-inferior to conven-
tional GC tapering with regard to the relapse-free sur-
vival rate) is supported by the results of the primary 
endpoint,  then rapid GC tapering may be established as 
the optimal tapering approach in patients with severe 
SLE.
Since high-dose GC therapy has many adverse 
effects,  the European League Against Rheumatism 
(EULAR) has already published recommendations on 
the management of medium- to high-dose GC therapy 
in rheumatic diseases [21].  The present study is 
expected to reduce the problems caused by these 
adverse effects in patients with severe SLE by reducing 
the cumulative GC dose.
It is possible that no patients in either study group 
will experience an SLE flare during the observation 
period.  If the overall SLE flare incidence is 0%,  the sta-
tistical analysis of the primary endpoint will not be 
applicable.  In that case,  we will report comparisons 
between the 2 groups in terms of the prevalence of 
LLDAS and any differences in therapeutic effects.
The primary outcome and the relapse-free survival 
rate as secondary outcomes are similar but not the 
same.  We consider that the primary outcome is ana-
lyzed cross-sectionally with Mann-Whitney’s U-test,  
and the relapse-free survival rate is analyzed over time 
with Kaplan-Meier curves and log-rank tests.
In patients with SLE,  the cumulative dose and the 
taper rate of GCs are of major concern.  This study is a 
clinically important trial that will directly compare con-
ventional and rapid GC tapering and will investigate the 
safety of the latter.
Recruitment.　This trial is currently being established.  Recruitment 
began at the first site on April 1,  2019.  The study’s start date was also April 
1,  2019.  The proposed end date is March 31,  2022 (the end of the fol-
low-up).
Funding process.　This trial is funded by the research fund of Juntendo 
University as a “CORE project.”
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